(Albany, USA) DelveInsight’s “Candidemia Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Candidemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Candidemia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Candidemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Candidemia market.
Request for a Free Sample Report @ Candidemia Market Forecast
Some facts of the Candidemia Market Report are:
- According to DelveInsight, Candidemia market size is expected to grow at a decent CAGR by 2034.
- Leading Candidemia companies working in the market are Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Scynexis, Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., Pfizer, and others.
- The candidemia market is expected to experience significant growth during the forecast period (2024–2034). This is a direct consequence of various market-driving factors such as the rising incidence of candidemia, increasing susceptible immune-compromised patient pool, increasing awareness of the disease, and the development of innovative treatment options.
- The Candidemia diagnosed incident population in the 7MM countries was estimated to be approximately 41,000+ cases in 2022, with the United States contributing approximately 23,000+ cases. Among EU4 and the UK, it was observed that Spain had the highest incidence rate of Candidemia.
- The United States is anticipated to dominate the Candidemia market among the 7MM during the forecast period.
- In January 2024, Cidara Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (U.K.) approved REZZAYO (rezafungin acetate) for the management of invasive candidiasis in adults. REZZAYO is a new once-weekly echinocandin licensed in the United States to treat candidemia and invasive candidiasis in adults.
- In November 2023, Basilea Pharmaceutica Ltd stated that it had signed an asset purchase agreement with Amplyx Pharmaceuticals, Inc., a Pfizer Inc. company, to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. Additionally, Basilea has purchased the rights to a preclinical antifungal chemical.
- In July 2023, T2 Biosystems, Inc. declared that the US Food and Drug Administration (FDA) granted Breakthrough Device status for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.
- In March 2023, the FDA approved Melinta Therapeutics’ and Cidara Therapeutics’ Rezzayo (rezafungin acetate) for the treatment of candidemia and invasive candidiasis in individuals who have limited or no other therapeutic choices. REZZAYO is the first new therapy option approved for candidemia and invasive candidiasis in over 15 years.
Candidemia Overview
Candidemia is a medical condition characterized by the presence of Candida species, particularly Candida albicans, in the bloodstream. Candida is a type of yeast that normally resides in various parts of the body, including the skin, gastrointestinal tract, and mucous membranes, without causing any harm. However, under certain circumstances, Candida can enter the bloodstream and cause an infection.
Candidemia typically occurs in individuals with weakened immune systems, such as those with HIV/AIDS, undergoing chemotherapy, or receiving immunosuppressive therapy. It can also affect patients who have undergone surgery, have central venous catheters, or are on prolonged antibiotic therapy.
Symptoms of candidemia may include fever, chills, rapid heart rate, low blood pressure, and sometimes skin rashes or lesions. The infection can spread to various organs and tissues, leading to more severe complications.
Learn more about Candidemia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/candidemia-market
Candidemia Market
The Candidemia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Candidemia market trends by analyzing the impact of current Candidemia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Candidemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Candidemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Candidemia market in 7MM is expected to witness a major change in the study period 2020-2034.
Candidemia Epidemiology
The Candidemia epidemiology section provides insights into the historical and current Candidemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Candidemia market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Candidemia Epidemiology @ Candidemia Prevalence
Candidemia Drugs Uptake
This section focuses on the uptake rate of the potential Candidemia drugs recently launched in the Candidemia market or expected to be launched in 2020-2034. The analysis covers the Candidemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Candidemia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Candidemia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Candidemia Pipeline Development Activities
The Candidemia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Candidemia key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Candidemia pipeline development activities @ Candidemia Drugs Market
Candidemia Therapeutics Assessment
Major key companies are working proactively in the Candidemia Therapeutics market to develop novel therapies which will drive the Candidemia treatment markets in the upcoming years are Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Scynexis, Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., Pfizer, and others.
Learn more about the emerging Candidemia therapies & key companies @ Candidemia Clinical Trials
Candidemia Report Key Insights
1. Candidemia Patient Population
2. Candidemia Market Size and Trends
3. Key Cross Competition in the Candidemia Market
4. Candidemia Market Dynamics (Key Drivers and Barriers)
5. Candidemia Market Opportunities
6. Candidemia Therapeutic Approaches
7. Candidemia Pipeline Analysis
8. Candidemia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Candidemia Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Candidemia Competitive Intelligence Analysis
4. Candidemia Market Overview at a Glance
5. Candidemia Disease Background and Overview
6. Candidemia Patient Journey
7. Candidemia Epidemiology and Patient Population
8. Candidemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Candidemia Unmet Needs
10. Key Endpoints of Candidemia Treatment
11. Candidemia Marketed Products
12. Candidemia Emerging Therapies
13. Candidemia Seven Major Market Analysis
14. Attribute Analysis
15. Candidemia Market Outlook (7 major markets)
16. Candidemia Access and Reimbursement Overview
17. KOL Views on the Candidemia Market
18. Candidemia Market Drivers
19. Candidemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/pipeline-assessment-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Candidemia Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight